AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

LBT Innovations Limited (AU:LBT) has released an update. LBT Innovations is making strides in the pharmaceutical environmental monitoring ...

Dominica announced that it will honour Prime Minister Narendra Modi with its highest national award during the India-CARICOM ...

AstraZeneca Pharma India Ltd. key Products/Revenue Segments include Pharmaceuticals and Sale of services for the year ending 31-Mar-2024.For the quarter ended 30-06-2024, the company has reported a ...

On the downside, the FMCG sector emerged as a significant drag on the indices, with Tata Consumer Products, HUL, Britannia ..

IST, the barometer index, the S&P BSE Sensex, was down 61.39 points or 0.08% to 77,629.56. The Nifty 50 index added 0.70 points or 0.0% to 23,558.35.

As per provisional closing, the S&P BSE Sensex declined 110.64 points or 0.14% to 77,580.31. The Nifty 50 index lost 26.35 points or 0.11% to 23,532.70.

This is despite the fact that most of the world's disease burden is concentrated in low and middle-income countries (LMICs).

Stocks like Rashtriya Chemicals and Fertilizers, Torrent Power, PI Industries, Godrej Industries, Thomas Cook India, ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...